Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis
Cancer · 01.10.2026 · 132 (19)
DOI: 10.1002/cncr.70614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 24.09.2026. Verfasst von Hira Mian und 31 weiteren Autor:innen. Beteiligte Einrichtung: Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Frailty, Immunotherapy, Adoptive. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).
Methods
Using the Center for International Blood and Marrow Transplant Research registry, this study evaluated outcomes of frail patients receiving commercial cilta‐cel from March 2022 to December 2023. Frailty was defined by an adapted simplified score incorporating age, performance status, and comorbidities.
Results
Among 541 patients with available frailty status, 183 (33.8%) were frail and 358 (66.2%) were nonfrail. Overall response rates were comparable (frail 82.8% vs. nonfrail 88.5%). However, frail patients had inferior progression‐free survival (PFS) (12‐month PFS, 62.7% [95% confidence interval (CI), 53.6%–71.3%] vs. 75.9% [95% CI, 70.4%–81.1%]; p < .01) and overall survival (OS) (12‐month OS 72.8% [95% CI, 64.9%–80.0%] vs. 90.4% [95% CI, 86.6%–93.7%]; p < .01). Twelve‐month treatment‐related mortality in frail patients was 6.8% (95% CI, 3.4%–11.2%) versus 3.6% (95% CI, 1.8%–6.1%), p = .12. Cytokine release syndrome (grade ≥2) occurred in 22.4% of frail versus 17.9% of nonfrail patients ( p = .05), and immune effector cell–associated neurotoxicity (ICANS) of any grade was reported in 32.2% versus 17.6% ( p < .01). Rates of cranial nerve palsies and Parkinsonism were comparable. Prolonged cytopenia (>day 30) was more common in frail patients (30.6% vs. 21.2%; p < .01). On multivariable analysis, frailty independently predicted worse PFS (hazard ratio [HR], 1.67; 95% CI, 1.16–2.40), OS (HR, 2.46; 95% CI, 1.57–3.87), and higher odds of any‐grade ICANS (odds ratio, 2.01; 95% CI, 1.32–3.08) (all p < .01).
Conclusions
Cilta‐cel remains effective in frail RRMM, but frailty is associated with reduced survival and increased toxicity, supporting tailored CAR‐T strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
- OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
- Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin, USA.
- Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- University of Kansas Medical Center, Kansas City, Kansas, USA.
- University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, USA.
ORCID-Profile: Rahul Banerjee, Binod Dhakal, Ashley E Rosko, Taiga Nishihori, Meera Mohan
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- National Institute of Allergy and Infectious Diseases
- HRSA HHS
Zitieren
APA
Mian, H., Faisal, M. S., Chen, T., Brazauskas, R., Oloyede, T., Ahmed, N., Afrough, A., Anderson, L. D., Banerjee, R., Berdeja, J., Bidikian, A., Devos, J., Dhakal, B., Dias, A., Dima, D., Efebera, Y. A., Gowda, L., Hansen, D. K., Hashmi, H., …, & Mohan, M. (2026). Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer, 132(19). https://doi.org/10.1002/cncr.70614
Vancouver
Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, et al. Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer. 2026;132(19). doi:10.1002/cncr.70614
BibTeX
@article{Mian2026,
author = {Mian, Hira and Faisal, Muhammad Salman and Chen, Tiening and Brazauskas, Ruta and Oloyede, Temitope and Ahmed, Nausheen and Afrough, Aimaz and Anderson, Larry D and Banerjee, Rahul and Berdeja, Jesus and Bidikian, Aram and Devos, Jakob and Dhakal, Binod and Dias, Ajoy and Dima, Danai and Efebera, Yvonne A and Gowda, Lohith and Hansen, Doris K and Hashmi, Hamza and Landau, Heather J and Lekakis, Lazaros and Mirza, Abu-Sayeef and Narra, Ravi and Patel, Krina and Rosko, Ashley E and Schroeder, Mark and Sidana, Surbhi and Usmani, Saad and Pasquini, Marcelo C and Nishihori, Taiga and Akhtar, Othman Salim and Mohan, Meera},
title = {Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis},
journal = {Cancer},
year = {2026},
volume = {132},
number = {19},
doi = {10.1002/cncr.70614}
}
EUVIMED